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ABSTRACT
Background: Candiduria is a common finding. However, in immunocompromised patients like HIV-infected individuals, it has high risk of 
morbidity and mortality as it could be a pointer to systemic candidiasis. Unfortunately, there are no clear criteria for differentiating between 
colonization and infection or between upper or lower urinary tract infections.
Objective: This study focused on determining the spectrum of Candida species implicated in candiduria among HIV-infected individuals and their 
susceptibility to fluconazole and voriconazole in a tertiary hospital.Methods: A total of 300 subjects comprising of 200 HIV patients and 100 non-
HIV individuals were used for this study. Clean catch midstream were collected from each individual and processed using standard microbiological 
techniques.  Emergent Candida isolates were identified with CHROMagar Candida and sugar fermentation tests.Results: The overall prevalence of 
candiduria among HIV patients was 13.5%. HAART-naive patients had a significantly higher prevalence (OR=4.165, 95%CI=1.602, 10.828; P=0.0038) 
than their counterpart on highly active antiretroviral therapy (HAART). Female gender was a significant risk factor for acquiring candiduria. Age 
had no significant effect on the prevalence of candiduria in this study. A CD4+ count <200 cells/µl was a significant risk factor for acquiring 
candiduria only among HAART-naive patients (OR=11.711; 95%CI=3.943, 34.780; P= 0.0001). The three species of Candida recovered from this study 
were C. albicans, C. krusei and C.parapsilosis. C. albicans (64.52%, 83.36%) and C. krusei (66.67%, 100.00%) were resistant to fluconazole and 
voriconazole respectively.Conclusion: There is a significant relationship between antiretroviral therapy, CD4+ counts, and the prevalence of 
candiduria among the study population.
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RÉSUMÉ
Contexte: La candidurie est un problème commun de sante publique. Cependant, chez les patients immunodéprimés comme les 
individus infectés par le VIH, elle présente un risque élevé de morbidité puisqu’elle peut évoluer vers la candidose systémique. 
Malheureusement, il n'existe pas de critères clairs permettant de distinguer la colonisation et l'infection de même que les 
infections des voies urinaires supérieures et inférieures.
Objectif: Cette étude a porté sur la détermination du spectre d'espèces de Candida impliqués dans la candidurie chez les 
personnes infectées par le VIH et leur sensibilité au fluconazole et voriconazole dans un hôpital tertiaire. Methodes : Un total de 
300 sujets comprenant 200 patients atteints du VIH et 100 personnes non -VIH ont été utilisés dans cette étude. Les echantillons 
d’urine ont été collectées auprès de chaque personne par la methode de ‘‘Clean catch midstream’’et traitées en utilisant des 
techniques microbiologiques standard. Les isolats émergents de Candida ont été identifiés avec CHROMagar Candida et les 
tests de fermentation de sucre. Résultats : La prévalence globale du VIH chez les patients atteints de candidurie était de 13,5%. 
Les patients en naïfs de la multithérapie HAARTavaient une prévalence significativement plus élevée (OR = 4,165, IC à 95% = 
85
1,602, 10,828, p = 0,0038 ) par rapport a leurs homologues sous traitement antirétroviral hautement actif (HAART ) . Le sexe 
féminin était un facteur de risque important d'acquisition de candidurie. L'âge n'avait pas d'effet significatif sur la prévalence 
de candidurie dans cette étude. Un compte de CD4 + < 200 cellules / µl n’a été un facteur de risque important pour l'acquisition 
de candidurie que chez les patients en multithérapie naïfs (OR = 11,711 ; IC à 95% = 3, 943, 34, 780, p = 0,0001). Les trois espèces 
de Candida récupérés de cette étude étaient C. albicans, C. krusei et C.parapsilosis. C. albicans(64,52%, 83,36 %) et C. krusei 
(66,67%, 100,00 %) étaient résistants respectivement au fluconazole et voriconazole. Conclusion: Il existe une relation 
significative entre le traitement antirétroviral, CD4 +, et la prévalence de candidurie parmi la population de l'étude.
.
Mots-clés: multithérapie HAART , naïfs , candidurie , CD4 + , Candida , prévalence .
INTRODUCTION 
Acquired immunodeficiency syndrome (AIDS) cause 
by human immunodeficiency virus (HIV) is the most 
important public health problem of modern times (1). 
HIV/AIDS continues to spread globally and remains 
a worldwide pandemic affecting about 40 million 
people (2). The pandemic is the leading cause of death 
in sub-Sahara Africa and the fourth leading cause of 
mortality worldwide and over 95% of these deaths 
have occurred among young adults in the developing 
world (3-4).
Fungal infections caused by yeast pathogens remain 
quite common in immunocompromised host, 
especially in HIV-infected individuals (5). These 
infections are playing an increasing important role in 
the morbidity and mortality of HIV/AIDS patients 
(6). Although the use of highly active antiretroviral 
therapy (HAART) has decreased the incidence of 
fungal infections (7-8), candidiasis continues to afflict 
HIV-infected individuals in HAART era (6, 9). 
Unfortunately, prolong use of antifungal among this 
population has led to increased incidence of 
resistance (10).  
The healthy urinary tract is sterile so the presence of 
Candidaspecies in urine or candiduria represent a 
variety of clinical situations (11-13), such as 
contamination of urine specimen, colonization of
bladder due to indwelling catheters, infection of 
upper or lower urinary tract, and primary or 
disseminated candidiasis (13-15).
Candidaspecies are the most commonly recovered 
fungi from urine (16) with C. albicans being the most 
frequently isolated, accounting for 50-70% of isolates 
in various studies (15, 17).  Others non-albicans such 
as C. glabrata and C. tropicalis are the next most 
common species while C. parapsilosis is commonly 
found in urine of neonates and is usually associated 
with systemic infection in this population (18).
Conditions that predispose to candiduria  includes 
immunosuppresion, use of broad spectrum antibiotic, 
gender, age, diabeties mellitus, chronic renal failure, 
malignancy, urinary tract abnormalities, pregnancy, 
and neutropenia (16, 19-23).
Asymptomatic candiduria is usually benign in most 
patients and do not require antifungal medication 
(24). However, in immunocompromised patients, it 
has a high risk of morbidity and mortality (25). There 
is little or no report on candiduria among HIV-
infected individuals in our locality, thus this study 
focused on determining the spectrum of Candida
species implicated in candiduria among HIV-infected 
individuals and their susceptibility to fluconazole and 
voriconazole.
MATERIALS AND METHODS                                       
Study Area
The study was carried out in the University of Benin 
Teaching Hospital, Benin City, Nigeria. It is located in 
the South-South geopolitical zone of Nigeria. It serves 
as a referral hospital to about six to ten states in 
Nigeria. It is a centre for Institute of Human Virology, 
Nigeria and US President’s Emergency Plan for AIDS 
Relief (PEPFAR) HIV/AIDS interventions in the zone.
Study Population
A total of 300 individuals consisting of 200 HIV 
patients and 100 (42 males and 58 females) apparently 
healthy, aged-matched, non-HIV individuals were 
recruited for this study. The patients consists of 100 
(31 males and 69 females) HAART-naïve patients and 
100 (22males and 78 females) HIV patients on 
HAART for 3-6 months. The HAART regimen 
included stavudine, zidovudine, and nevirapine. The 
HIV patients were out-patients and asymptomatic. 
Informed consent was obtained from all individuals 
prior to specimen collection. The Ethical Committee 
of the University of Benin Teaching Hospital 
approved the protocol for this study.
Specimen collection and processing
Venous blood (5ml) was collected into ethylene 
diamine tetraacetic acid (EDTA) container and mixed. 
Clean-catch mid-stream urine was collected into 
sterile universal container containing few crystals of 
boric acid as preservative (26). 
The blood specimens were used for CD4 counts using 
flow cytometry (Partec, Germany) following 
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manufacturer’s instruction.  A loop-full (0.001ml) of 
well mixed un-centrifuged urine was streaked onto 
the surface of Saboraund’s Dextrose Agar (SDA) and 
Brain Heart Infusion Agar (BHIA) containing 5µg/ml 
gentamicin. The plates were incubated aerobically at 
370C for 24-48 hours and counts were expressed in 
colony forming unit per ml. A count of ≥ 105 cfu/ml 
was considered significant to indicate asymptomatic 
candiduria. The urine specimens were centrifuged at 
2000 g for 5minutes. The supernatant was discarded 
and a drop of the deposit was examined 
microscopically at high magnification for pus cells. 
Pus cells ≥5 per high power field were considered to 
indicate infection (26). 
Emergent yeast colonies were stored for 
identification.  All Candida isolates were identified 
with CHROMagarTMCandida (Paris, France) as 
previously described (27) and sugar fermentation 
tests as described by Forbes et al., (28).Antifungal 
susceptibility test was performed using the CLSI (29) 
disc diffusion methods.  Voriconazole disc (1µg)and 
fluconazole disc (25µg) (Oxoid, England) were used 
for this study.
RESULTS
The prevalence of candiduria among HIV and non-
HIV individuals is shown in table 1. HIV status was a 
significant risk factor for acquiring candiduria 
(OR=3.746; 95%CI=1.273, 11.025; P=0.0189). 
Considering HIV status, the prevalence of candiduria 
among HAART-naïve patients was significantly 
higher than HIV patients on HAART (P= 0.0038). 
Female gender was significantly associated with 
candiduria.
TABLE 1: PREVALENCE OF CANDIDURIA AMONG HIV AND NON-HIV INDIVIDUALS.














Non HIV 42 - 58 4 (6.70) 100 4 (4.00) C. albicans
Mixed 
Infection
42 - 58 - 100 - -
HIV patients
HAAT naive× 31 1 (3.23) 69 20 (28.99) 100 21 (21.00) C. albicans, C. parapsilosis
Mixed 
Infection
31 - 69 3 (4.35) 100 3 (3.00) C. krusei , C.albicans
On 
HAARTβ,α
22 - 78 6 (7.69) 100 6 (6.00) C. albicans, C. krusei
Mixed 
Infection
22 - 78 1 (1.28) 100 1 (1.00)
HIV versus non-HIV:  OR=3.746; 95%CI=1.273, 11.025; P=0.0189; βOn HAART versus non-HIV:  OR=1.532; 95%CI=0.4187, 5.604;  
P=0.7475. ×HAART naive versus non-HIV:   OR=6.380; 95%CI=2.102, 19.362; P=0.0006. αHAART naive versus on HAART:  
OR=4.165, 95%CI=1.602, 10.828; P=0.0038
Only one male among HAART-naive HIV patient had 
candiduria. The prevalence of candiduria did not 
differ significantly (P= 0.7475) between HIV patients 
on HAART and non-HIV individuals.
Table 2 show Candida isolates recovered from HIV 
and non-HIV individuals. C. albicans was still the 
most prevalent and the only isolate recovered from 
non-HIV individuals. C. krusei was recovered from 
HIV patients on HAART and HAART-naïve while C. 
parapsilosis were recovered only from HAART-naïve 
HIV patients.
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TABLE 2: CANDIDA ISOLATES RECOVERED FROM URINE OF HIV AND NON-HIV INDIVIDUALS
Organisms Non-HIV (%) HAART-naïve (%) On HAART (%) Total (%)
C. albicans 4 (100.00) 20 (86.96) 7 (87.50) 31 (88.57)
C. krusei - 2 (8.70) 1 (12.50) 3 (8.57)
C. Parapsilosis - 1 (4.45) - 1 (2.86)
TABLE 3: CANDIDA ISOLATES RECOVERED FROM URINE OF HIV AND NON-HIV INDIVIDUALS IN RELATION TO 
GENDER
Organisms                Non-HIV         HAART-naive        On HAART
Male (%) Female (%) Male (%) Female (%) Male (%) Female (%) Male (%) Female (%)
C. albicans - 4 (100.00) 1 (100.00) 19 (82.61) 4 (80.00) 7 (87.50) 1 (100.00) 30 (85.71)
C. krusei - - - 2 (8.70) - 1 (12.50) - 3 (8.52)
C. parapsilosis - - - 1 (4.35) - - - 1 (2.86)
Table 3 show Candida isolates recovered from HIV 
and non-HIV individuals in relation to gender. 
All C. albicans recovered from non-HIV individuals 
were from female. Similarly, C. krusei, and C. 
parapsilosis were recovered from female HIV patients.
TABLE 4: PREVALENCE OF CANDIDURIA AMONG HIV AND NON-HIV INDIVIDUALS IN RELATION TO AGE
Age                   Non-HIV             HAART-naive                On HAART
Years No. sampled No. infected (%) No. sampled No. infected (%) No. sampled No. infected (%)
11-20 5 - - - - -
21-30 40 2 (5.0) 15 2 (13.3) 14 -
31-40 34 1 (2.9) 48 15 (31.3) 47 4 (8.5)
41-50 17 1 (5.9) 32 5 (15.6) 29 2 (6.9)
51-60 3 - 4 1 (25.0) 7 1 (14.3)
61-70 1 - 1 - 3 -
Non-HIV; P=0.9810; HAART-naïve; P=0.4160; On HAART; P=0.7329
TABLE 5. EFFECT OF CD4 COUNTS ON PREVALENCE OF CANDIDURIA AMONG HIV INDIVIDUALS
CD4 Counts      No. sampled   No. infected (%)   OR          95%CI                P. value            Candida isolates
(Cells/µl)
HAART naïve
<200                      32                17(53.13)           11.711      3.943,  34.780        0.0001             C. albicans
≥200                      68                 6(8.82)              0.085        0.029,  0.254                                  C. albicans, C. parapsilosis
Mixed Infection
<200                      32                 4(12.50)            21.632      1.127,  415.35        0.0152             C. albicans, C. krusei,
≥200                      68                  -                        0.046        0.002,  0.888
On HAART
<200                      12                  2(16.67)            3.320        0.567,  19.426        0.4260             C. albicans
≥200                      88                  5(5.68)              0.301        0.052,  1.762                                  C. albicans
Mixed Infection
<200                      12                   1(8.33)            23.087       0.886,  601.310       0.2399             C. albicans, C. krusei
≥200                    88                   -                 0.043        0.002,  1.128                                                                              
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Age had no significant effect on the prevalence of 
candiduria in this study (Table 4).
CD4 <200cells/µl was significantly associated with 
candiduria. However, among HIV patients on 
HAART, CD4<200cells/µl did not significantly affect 
the prevalence of candiduria (Table 5).
Among the yeasts recovered, more C. albicans and C. 
krusei were resistant to fluconazole and voriconazole. 
The only isolate of C. parapsilosis was susceptible to 
both antifungal agents (Table 6).
TABLE 6: ANTIFUNGAL SUSCEPTIBILITY PROFILE OF CANDIDA ISOLATES
Organisms                FLUCONAZOLE                            VORICONAZOLE
                        S (%)        S-DD (%)    R (%)            S (%)          S-DD (%)      R (%)
C. albicans         9(29.03)      2(6.45)        20(64.52)      10(90.91)    2(100.00)    19(83.36)
C. krusei            1(33.33)            -          2(66.67)            -                     -             3(100.00)
C. parapsilosis   1(100.00)          -                  -               1(100.00)        -                    -
DISCUSSION
Fungal infections are playing an increasing important 
role in the morbidity and mortality of HIV/AIDS 
patients (6). Although the use of highly active 
antiretroviral therapy (HAART) has decreased the 
incidence of fungal infections (7-8), candidiasis 
continues to afflict HIV-infected individuals in 
HAART era (6, 9). 
Recent studies have shown that candiduria is getting 
increased due to immunocompromised patients; 
prolong hospitalization, uncontrolled use of 
antibiotic, prophylaxis by antifungal agents, urinary 
tract surgeries (11, 30-31). Candiduria accounted for 
up to 10% of UTIs and has resulted in increased rate 
of mortality during the last decades due to use of new 
treatments, surgery and transplantation (14, 32-33).
In this study, the overall prevalence of candiduria 
among HIV-infected individual was 13.5%. This is 
lower than 22% reported in Brazil among hospitalized 
patients (35). HIV status was significantly associated 
with candiduria (OR=3.746; 95%CI=1.273, 11.025; 
P=0.0189). HIV results in immunosuppression which 
has been reported as a risk factor for acquiring 
candiduria (11). However, in regard to treatment 
status, the prevalence of candiduria among HIV 
patients on HAART (6%) have no significant different 
with non-HIV (4%) individuals. This indicates that 
candiduria in HAART-naïve HIV patients contributed 
to the significant difference in prevalence among HIV 
and non-HIV individuals. Thus as, HAART improves 
immunity, candiduria decreases to almost the same 
prevalence with that of non-HIV individuals.
Candida albicans (88.57%) was the most predominant 
isolate recovered. This agrees with the report of 
previous investigators (11, 16, 24). Other species of 
Candida recovered includes C.krusei (8.57%) and C. 
parapsilosis (2.86%). These species of Candida have 
previously been reported as causes of candiduria (16, 
35).Irrespective of HIV status and treatment status, 
the female gender was associated with candiduria in 
this study. This is in agreement with the report of 
previous investigators (14, 19, 22).In this study, 
increased age had no significant effect on the 
prevalence of candiduria. This does not agree with 
the report of Kauffman, (14). The reason for this is 
unclear.
Among HAART-naïve HIV patients, CD4<200cells/µl 
was associated with candiduria (Table 5). It has been 
reported that fungal agents such as Candida takes 
advantage of the immune suppression seen in HIV 
among HIV patients as a result of CD4 T cells 
depletion (35). This may explain the findings in this 
study. It has also been reported from a number of 
experimental studies that acquired resistant to 
Candida infection is dependent upon the participation 
of T-lymphocytes (35). HAART causes a decline in the 
incidence of some opportunistic infection in AIDS and 
this decline is currently attributed to restoration of 
immunity and anti Candida activity of protease 
inhibitors among the HAART regimen (35). This may 
explain the non significant difference in the 
prevalence of candiduria among HIV patients on 
HAART with CD4<200cells/µl and CD4≥200cells/µl. 
However, protease inhibitors were not among the 
HAART regimen for our HIV patients on HAART. 
This may therefore indicate that immune 
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reconstitution may account for the observed results 
among HIV patients on HAART in relation to 
candiduria.Most of C. albicans (64.52%, 83.36%) and C. 
krusei (66.67%, 100.00%) were resistant to fluconazole 
and voriconazole respectively.  It has been reported 
that Candida species from HIV patients are more 
resistant to antifungal agents (36-37). Prolong used of 
antifungal among HIV patients has been reported as 
predisposing factor (10).
In conclusion, there is a significant relationship 
between antiretroviral therapy, CD4+ counts, and the 
prevalence of candiduria among HIV patients.  
Therefore candiduria should be verified by obtaining 
a second specimen and appropriate therapy instituted 
after antifungal susceptibility teststo prevent systemic 
candidiasis amongthis population.
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